149 related articles for article (PubMed ID: 23442069)
1. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
4. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
5. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
6. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
7. Therapeutic application of GPR119 ligands in metabolic disorders.
Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
[TBL] [Abstract][Full Text] [Related]
8. Direct activation of the proposed anti-diabetic receptor, GPR119 in cardiomyoblasts decreases markers of muscle metabolic activity.
Cornall LM; Hryciw DH; Mathai ML; McAinch AJ
Mol Cell Endocrinol; 2015 Feb; 402():72-85. PubMed ID: 25578601
[TBL] [Abstract][Full Text] [Related]
9. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
10. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
[TBL] [Abstract][Full Text] [Related]
11. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus.
Mo XL; Yang Z; Tao YX
Prog Mol Biol Transl Sci; 2014; 121():95-131. PubMed ID: 24373236
[TBL] [Abstract][Full Text] [Related]
12. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
Kang SU
Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
[TBL] [Abstract][Full Text] [Related]
13. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder.
Zhang S; Ma Y; Li J; Ma J; Yu B; Xie X
Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14571-6. PubMed ID: 25246581
[TBL] [Abstract][Full Text] [Related]
14. GPR119 as a fat sensor.
Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
[TBL] [Abstract][Full Text] [Related]
15. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.
Hassing HA; Engelstoft MS; Sichlau RM; Madsen AN; Rehfeld JF; Pedersen J; Jones RM; Holst JJ; Schwartz TW; Rosenkilde MM; Hansen HS
Biofactors; 2016 Nov; 42(6):665-673. PubMed ID: 27297962
[TBL] [Abstract][Full Text] [Related]
16. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
Kogure R; Toyama K; Hiyamuta S; Kojima I; Takeda S
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):58-63. PubMed ID: 22079287
[TBL] [Abstract][Full Text] [Related]
17. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
18. Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
Syed SK; Bui HH; Beavers LS; Farb TB; Ficorilli J; Chesterfield AK; Kuo MS; Bokvist K; Barrett DG; Efanov AM
Am J Physiol Endocrinol Metab; 2012 Dec; 303(12):E1469-78. PubMed ID: 23074242
[TBL] [Abstract][Full Text] [Related]
19. GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes.
Cornall LM; Mathai ML; Hryciw DH; Simcocks AC; O'Brien PE; Wentworth JM; McAinch AJ
Mol Cell Endocrinol; 2013 Jan; 365(1):108-18. PubMed ID: 23069642
[TBL] [Abstract][Full Text] [Related]
20. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders.
Tiwari A; Maiti P
Drug Discov Today; 2009 May; 14(9-10):523-30. PubMed ID: 19429513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
